BRKR:NGS-Bruker Corporation (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 93.86

Change

+1.46 (+1.58)%

Market Cap

USD 3.67B

Volume

0.33M

Analyst Target

USD 47.92
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bruker Corp is designer and manufacturer of life science & materials research systems in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology & in-vitro diagnostics industries.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 49.24B
ALGN Align Technology Inc

N/A

USD 23.26B
SWAV Shockwave Medical Inc

N/A

USD 12.34B
PODD Insulet Corporation

N/A

USD 11.64B
MASI Masimo Corporation

N/A

USD 7.20B
IRTC iRhythm Technologies Inc

N/A

USD 3.48B
AXNX Axonics Modulation Technologie..

N/A

USD 3.40B
TMDX TransMedics Group Inc

N/A

USD 3.02B
LIVN LivaNova PLC

N/A

USD 3.00B
QDEL Quidel Corporation

N/A

USD 2.65B

ETFs Containing BRKR

TYNE 12.61 % 0.00 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 4.11 % 0.57 %

N/A

USD 1.08B
JSMD Janus Henderson Small/Mid.. 2.77 % 0.50 %

N/A

USD 0.34B
FITE SPDR S&P Kensho Future Se.. 2.12 % 0.20 %

N/A

USD 0.05B
QRH:CA 0.00 % 1.20 %

N/A

N/A
KOMP SPDR Kensho New Economies.. 0.00 % 0.00 %

N/A

USD 1.80B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

CAD 0.30B
HLTH:AU VanEck Global Healthcare .. 0.00 % 0.00 %

N/A

USD 0.06B
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 6.45M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 6.45M

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.74% 85% B 85% B
Dividend Return 0.07% 100% F 2% F
Total Return 27.80% 85% B 85% B
Trailing 12 Months  
Capital Gain 21.39% 78% C+ 74% C
Dividend Return 0.26% 50% F 2% F
Total Return 21.65% 79% B- 73% C
Trailing 5 Years  
Capital Gain 144.17% 89% A- 87% B+
Dividend Return 2.32% 100% F 9% A-
Total Return 146.49% 89% A- 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 17.01% 68% D+ 78% C+
Dividend Return 17.33% 69% C- 78% C+
Total Return 0.32% 50% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 36.93% 78% C+ 49% F
Risk Adjusted Return 46.91% 92% A 80% B-
Market Capitalization 3.67B 98% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.80 48% 30%
Price/Book Ratio 9.38 16% 12%
Price / Cash Flow Ratio 36.92 10% 8%
Price/Free Cash Flow Ratio 20.45 12% 12%
Management Effectiveness  
Return on Equity 33.67% 99% 95%
Return on Invested Capital 14.57% 92% 84%
Return on Assets 7.70% 96% 92%
Debt to Equity Ratio 84.25% 33% 27%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector